Distinct subsets of neutrophils crosstalk with cytokines and metabolites in patients with sepsis
Sepsis is a life-threatening condition caused by a dysregulated host response to infection. Despite continued efforts to understand the pathophysiology of sepsis, no effective therapies are currently available. While singular components of the aberrant immune response have been investigated, compreh...
Saved in:
Published in: | iScience Vol. 26; no. 2; p. 105948 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Elsevier Inc
17-02-2023
Elsevier |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Sepsis is a life-threatening condition caused by a dysregulated host response to infection. Despite continued efforts to understand the pathophysiology of sepsis, no effective therapies are currently available. While singular components of the aberrant immune response have been investigated, comprehensive studies linking different data layers are lacking. Using an integrated systems immunology approach, we evaluated neutrophil phenotypes and concomitant changes in cytokines and metabolites in patients with sepsis. Our findings identify differentially expressed mature and immature neutrophil subsets in patients with sepsis. These subsets correlate with various proteins, metabolites, and lipids, including pentraxin-3, angiopoietin-2, and lysophosphatidylcholines, in patients with sepsis. These results enabled the construction of a statistical model based on weighted multi-omics linear regression analysis for sepsis biomarker identification. These findings could help inform early patient stratification and treatment options, and facilitate further mechanistic studies targeting the trifecta of surface marker expression, cytokines, and metabolites.
[Display omitted]
•Integrated systems immunology approach reveals unique neutrophil subsets in sepsis•Multi-omics modeling reveals biomarkers including neutrophil CD10, PTX3, and lysoPC•These findings could enable future mechanistic studies and patient stratification
Immunity; Components of the immune system; Cell biology; Systems biology |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Eikon Therapeutics, New York City, NY, USA Present address: ProFound Therapeutics, Boston, MA, USA Present address: Verge Genomics, South San Francisco, CA, USA Present address: Third Rock Ventures, Boston, MA, USA These authors contributed equally Lead contact |
ISSN: | 2589-0042 2589-0042 |
DOI: | 10.1016/j.isci.2023.105948 |